Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway

Introduction: Glioblastoma (GBM) is invariably resistant to temozolomide (TMZ) chemotherapy. Inhibiting the proteasomal pathway is an emerging strategy to accumulate damaged proteins and inhibit their lysosomal degradation. We hypothesized that pre-treatment of glioblastoma with bortezomib (BTZ) mig...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahman, Mohummad Aminur, Engelsen, Agnete S. T., Sarowar, Shahin, Bindesbøll, Christian, Birkeland, Even, Goplen, Dorota, Lotsberg, Maria L., Knappskog, Stian, Simonsen, Anne, Chekenya, Martha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814514/
https://www.ncbi.nlm.nih.gov/pubmed/36619857
http://dx.doi.org/10.3389/fcell.2022.1022191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814514/
https://www.ncbi.nlm.nih.gov/pubmed/36619857
http://dx.doi.org/10.3389/fcell.2022.1022191

Ejemplares similares